Connection
Paul Bunn to Signal Transduction
This is a "connection" page, showing publications Paul Bunn has written about Signal Transduction.
|
|
Connection Strength |
|
 |
|
 |
|
0.338 |
|
|
|
-
Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One. 2013; 8(12):e82236.
Score: 0.046
-
Bunn PA, Chan D, Dienhart DG, Tolley R, Tagawa M, Jewett PB. Neuropeptide signal transduction in lung cancer: clinical implications of bradykinin sensitivity and overall heterogeneity. Cancer Res. 1992 Jan 01; 52(1):24-31.
Score: 0.040
-
Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA, Heasley LE. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol. 2009 Jan; 75(1):196-207.
Score: 0.032
-
Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Bar?n A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res. 2006 Dec 01; 12(23):7117-25.
Score: 0.028
-
Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther. 2004 Aug; 3(8):977-83.
Score: 0.024
-
Bunn PA, Johnson DH. Seminars in oncology. Introduction. Semin Oncol. 2002 Feb; 29(1 Suppl 4):1-2.
Score: 0.020
-
Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol. 2002 Feb; 29(1 Suppl 4):3-14.
Score: 0.020
-
Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):37-46.
Score: 0.020
-
Bunn PA, Helfrich BA, Brenner DG, Chan DC, Dykes DJ, Cohen AJ, Miller YE. Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo. Clin Cancer Res. 1998 Nov; 4(11):2849-58.
Score: 0.016
-
Beekman A, Helfrich B, Bunn PA, Heasley LE. Expression of catalytically inactive phospholipase Cbeta disrupts phospholipase Cbeta and mitogen-activated protein kinase signaling and inhibits small cell lung cancer growth. Cancer Res. 1998 Mar 01; 58(5):910-3.
Score: 0.015
-
Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017 12; 17(12):725-737.
Score: 0.015
-
Bunn P, Carbone D, Grim J, Harris C, Havemann K, Mabry M, Roth J, Saijo N, Poulsen HS, Stahel R, Takahashi T, Twentyman P. Fifth I.A.S.L.C. Lung Tumor Biology Workshop, August 13-17, 1996, Ermatingen, Switzerland. Ann Oncol. 1997 Jan; 8(1):27-36.
Score: 0.014
-
Heasley LE, Zamarripa J, Storey B, Helfrich B, Mitchell FM, Bunn PA, Johnson GL. Discordant signal transduction and growth inhibition of small cell lung carcinomas induced by expression of GTPase-deficient G alpha 16. J Biol Chem. 1996 Jan 05; 271(1):349-54.
Score: 0.013
-
Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, B?hm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA, Camidge DR, Tan AC, Hirsch FR, Heasley LE. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014 Jun 15; 20(12):3299-309.
Score: 0.012
-
Cas?s-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA, Chan DC, Tan AC, DeGregori J. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 2012 Aug 15; 72(16):4154-64.
Score: 0.010
-
Kelly K, Kane MA, Bunn PA. Growth factors in lung cancer: possible etiologic role and clinical target. Med Pediatr Oncol. 1991; 19(6):450-8.
Score: 0.009
-
Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K, Miller YE. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res. 1996 Feb 15; 56(4):831-9.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|